Clinical Trial Update: A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC [Phase 3]

View source ↗

Summary

A Phase 3 trial compared HLX04 to Bevacizumab, each given with XELOX or mFOLFOX6 as first-line therapy in metastatic colorectal cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• HLX04 (HLX04)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Metastatic Colorectal Cancer (mCRC) | Phase 3 | Status: COMPLETED